We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
The current 0A4C market cap is 0. The company's latest EPS is USD -1.6462 and P/E is -5.47.
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Revenue | 5.8M | 8.19M | 4.41M | -68k | 426k |
| Operating Income | -20.47M | -54.8M | -85.92M | -87.74M | -95.93M |
| Net Income | -20.97M | -49.04M | -97.09M | -84.71M | -88.45M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Total Assets | 54.06M | 245.12M | 218.87M | 206.93M | 210.64M |
| Total Liabilities | 8.54M | 19.24M | 19.73M | 21.64M | 16.54M |
| Total Equity | 45.52M | 225.88M | 199.14M | 185.29M | 194.1M |
| Year End December 30 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| USD ($) | USD ($) | USD ($) | USD ($) | USD ($) | |
| Operating | -9.6M | -34.44M | -78.24M | -62.59M | -75.81M |
| Investing | -28.29M | -72.1M | 87.52M | -73.4M | 13.73M |
| Financing | 12.53M | 213.49M | 65.1M | 56.78M | 86.11M |
| Market Cap | 0 |
| Price to Earnings Ratio | -5.47 |
| Price to Sales Ratio | 1.14k |
| Price to Cash Ratio | 3.58 |
| Price to Book Ratio | 2.49 |
| Dividend Yield | - |
| Shares Outstanding | 53.73M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0 (0%) |
| Company Name | Altimmune Inc |
| Address |
1209 orange street wilmington, delaware 19801 |
| Website | https://www.altimmune.com |
| Industry | pharmaceutical preparations (2834) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: 1-888-992-3836 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
